HBPCF (Helix BioPharma) OCF Margin %: 0.00% (As of Apr. 2026)


HBPCF Helix BioPharma Corp HBPCF
28 GF Score
Price $1.71
View Full Analysis

What is Helix BioPharma OCF Margin %?

Helix BioPharma HBPCF 28 OCF Margin % is 0.00% as of Apr. 2026. GuruFocus rates HBPCF with a GF Score™ of 28/100. Among 960 Biotechnology companies, Helix BioPharma ranks worse than 104166.56% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Helix BioPharma's Cash Flow from Operations for the three months ended in Apr. 2026 was $-0.64 Mil. Helix BioPharma's Revenue for the three months ended in Apr. 2026 was $0.00 Mil. Therefore, Helix BioPharma's OCF Margin % for the quarter that ended in Apr. 2026 was 0.00%.

As of today, Helix BioPharma's current OCF Yield % is -3.16%.

The historical rank and industry rank for Helix BioPharma's OCF Margin % or its related term are showing as below:


HBPCF's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

Helix BioPharma OCF Margin % Related Terms

Helix BioPharma OCF Margin % Historical Data

* Premium members only.

The historical data trend for Helix BioPharma's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helix BioPharma OCF Margin % Chart

Helix BioPharma Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Helix BioPharma Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HBPCF
28GF Score
Helix BioPharma Corp HBPCF
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Helix BioPharma OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Helix BioPharma's OCF Margin for the fiscal year that ended in Jul. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Jul. 2025 )/Revenue (A: Jul. 2025 )
=-2.798/0
= %

Helix BioPharma's OCF Margin for the quarter that ended in Apr. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Apr. 2026 )/Revenue (Q: Apr. 2026 )
=-0.64/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Helix BioPharma (HBPCF) has a OCF Margin % of 0.00% as of Apr. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Helix BioPharma and its competitors. According to the industry distribution chart, Helix BioPharma ranks #999999 out of 960 companies in the Biotechnology industry.
Is Helix BioPharma's OCF Margin % too high?
Helix BioPharma's current OCF Margin % is 0.00%. Based on the distribution chart, Helix BioPharma ranks #999999 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Helix BioPharma has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Helix BioPharma's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Helix BioPharma ranks #999999 out of 960 companies for OCF Margin %. This places Helix BioPharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Helix BioPharma and its competitors. Helix BioPharma's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helix BioPharma stock overvalued right now?
Helix BioPharma (HBPCF) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Helix BioPharma's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Helix BioPharma (HBPCF), the current OCF Margin % is 0.00% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Helix BioPharma Business Description

Other Exchanges HBP0:GermanyHBP:Canada
Address 40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4
Helix BioPharma Corp is a clinical-stage biopharmaceutical company developing therapies in immune-oncology focused on cancer prevention and treatment. The Company is developing a proprietary platform of bio-conjugates targeting hard-to-treat solid tumors over-expressing CEACAM6, including Tumor Defense Breaker, L-DOS47, and three CEACAM6-specific antibody-drug conjugates. Its pre-IND candidates include LEUMUNA, an oral immune checkpoint modulator for hematological malignancies, and GEMCEDA, an oral prodrug of gemcitabine for solid tumors.
28GF Score

Get the complete analysis for HBPCF

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.71
Price